Nurix Therapeutics' GAAP loss for 2021 was $117.194 million, up 2.7 times from $43.242 million in the previous year. Revenue increased 66.9% to $29.75 million from $17.82 million a year earlier.
Nurix Therapeutics' GAAP loss for 2021 was $117.194 million, up 2.7 times from $43.242 million in the previous year. Revenue increased 66.9% to $29.75 million from $17.82 million a year earlier. 
ir.nurixtx.com
English (US) 